Abstract
Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 649-651 |
| Number of pages | 3 |
| Journal | Expert Review of Anti-Infective Therapy |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2011 |
Fingerprint
Keywords
- CCR5 antagonist
- maraviroc
- R5-tropic HIV
- randomized controlled trial
- triple-class failure
ASJC Scopus subject areas
- Infectious Diseases
- Microbiology (medical)
- Microbiology
- Virology
Cite this
Lessons from maraviroc clinical trials. / Troia-Cancio, Paolo; Asmuth, David.
In: Expert Review of Anti-Infective Therapy, Vol. 9, No. 6, 06.2011, p. 649-651.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lessons from maraviroc clinical trials
AU - Troia-Cancio, Paolo
AU - Asmuth, David
PY - 2011/6
Y1 - 2011/6
N2 - Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.
AB - Maraviroc is the first commercially available HIV chemokine receptor antagonist targeting HIV that utilizes the CCR5 chemokine receptor (R5 tropic). The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) trials were two randomized, placebo-controlled studies designed to demonstrate the activity of maraviroc in triple-class-experienced HIV individuals, with a primary end point of viral load suppression at 48 weeks. Maraviroc outperformed the placebo plus optimized background (OBT) arm, and exhibited a favorable safety profile with low discontinuation rates, which equaled those of the placebo plus OBT group. The results of these trials led to maraviroc receiving regulatory approval for the treatment of HIV.
KW - CCR5 antagonist
KW - maraviroc
KW - R5-tropic HIV
KW - randomized controlled trial
KW - triple-class failure
UR - http://www.scopus.com/inward/record.url?scp=79959756297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959756297&partnerID=8YFLogxK
U2 - 10.1586/eri.11.52
DO - 10.1586/eri.11.52
M3 - Article
C2 - 21692669
AN - SCOPUS:79959756297
VL - 9
SP - 649
EP - 651
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
SN - 1478-7210
IS - 6
ER -